PROKIDNEY CORP (PROK:NASDAQ)
$1.295 -0.175 (-11.9048%)
Analysed PROKIDNEY CORP (PROK:NASDAQ) News Sources
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
10-08-2026
yahoo.com
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
10-08-2026
yahoo.com
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
15-05-2026
yahoo.com
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel
01-05-2026
yahoo.com
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
15-05-2026
yahoo.com
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
17-06-2026
yahoo.com
ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict
11-09-2026
yahoo.com
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
22-10-2026
yahoo.com
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
22-10-2026
yahoo.com
ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500
28-10-2026
marketbeat.com
What is the current price of PROKIDNEY CORP (PROK:NASDAQ)?
The current price of PROKIDNEY CORP (PROK:NASDAQ) is $1.295.
PROKIDNEY CORP (PROK:NASDAQ) absolute price change since previous trading day?
The absolute price change of PROKIDNEY CORP (PROK:NASDAQ) since the previous trading day is $-0.175.
PROKIDNEY CORP (PROK:NASDAQ) percentage price change since previous trading day?
The percentage price change of PROKIDNEY CORP (PROK:NASDAQ) since the previous trading day is -11.9048%.
What is the most recent average sentiment score for PROKIDNEY CORP (PROK:NASDAQ)?
The most recent average sentiment score for PROKIDNEY CORP (PROK:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for PROKIDNEY CORP (PROK:NASDAQ)?
The most recent sentiment for PROKIDNEY CORP (PROK:NASDAQ) is .
SEC-8K** Filing Available For PROKIDNEY CORP (PROK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.